Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$39.31 +0.8%	$40.41	$26.20 ▼ $63.50	$1.81B	1.47	612,843 shs	824,624 shs
CGEM Cullinan Therapeutics	$7.53 -3.1%	$8.02	$6.85 ▼ $21.01	$458.54M	-0.08	497,182 shs	221,414 shs
IMCR Immunocore	$36.31 +0.3%	$33.35	$23.15 ▼ $40.88	$1.82B	0.77	338,237 shs	210,685 shs
OCUL Ocular Therapeutix	$11.33 -0.4%	$8.80	$5.79 ▼ $11.78	$1.81B	1.43	1.44 million shs	2.13 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	+0.79%	+3.07%	-4.54%	+18.73%	-20.12%
CGEM Cullinan Therapeutics	-3.09%	-2.21%	-7.72%	-4.56%	-59.32%
IMCR Immunocore	+0.28%	+3.68%	+14.54%	+27.81%	-6.90%
OCUL Ocular Therapeutix	-0.44%	+2.72%	+36.01%	+54.99%	+41.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.0157 of 5 stars	3.5	3.0	0.0	2.0	4.2	0.0
CGEM Cullinan Therapeutics	1.9473 of 5 stars	3.5	0.0	0.0	2.7	1.7	0.6
IMCR Immunocore	1.482 of 5 stars	3.3	0.0	0.0	2.1	2.5	0.0
OCUL Ocular Therapeutix	3.6489 of 5 stars	3.5	2.0	4.1	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	151.84% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	298.41% Upside
IMCR Immunocore	2.55	Moderate Buy	$58.89	62.18% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	52.99% Upside

Current Analyst Ratings Breakdown

Latest CGEM, OCUL, APGE, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $115.00
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/8/2025	IMCR Immunocore	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $86.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
IMCR Immunocore	$310.20M	5.88	N/A	N/A	$7.20 per share	5.04
OCUL Ocular Therapeutix	$59.65M	30.26	N/A	N/A	$2.01 per share	5.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.43	N/A	N/A	N/A	-6.48%	-5.86%	-2.09%	8/6/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)

Latest CGEM, OCUL, APGE, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.7951	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	IMCR Immunocore	-$0.21	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.08	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	N/A	N/A	N/A	$13.12 million	N/A
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	15.82	15.82
CGEM Cullinan Therapeutics	N/A	11.62	11.62
IMCR Immunocore	1.03	6.36	6.31
OCUL Ocular Therapeutix	0.26	10.22	10.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CGEM Cullinan Therapeutics	86.31%
IMCR Immunocore	84.50%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
CGEM Cullinan Therapeutics	7.16%
IMCR Immunocore	10.40%
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
CGEM Cullinan Therapeutics	30	59.01 million	54.79 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable

CGEM, OCUL, APGE, and IMCR Headlines

Recent News About These Companies

Brokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $17.33

July 13, 2025 | americanbankingnews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Buy" from Analysts

July 10, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 5.5% - Here's What Happened

July 8, 2025 | marketbeat.com

847,468 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Peregrine Capital Management LLC

July 1, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 7.7% - What's Next?

June 30, 2025 | marketbeat.com

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Nasdaq

June 27, 2025 | nasdaq.com

Ocular Therapeutix sharpens focus with retina-centric rebrand

June 27, 2025 | fiercepharma.comF

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

June 26, 2025 | finance.yahoo.com

Ocular Therapeutixâ„¢ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

June 26, 2025 | globenewswire.com

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

June 25, 2025 | zacks.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - Here's Why

June 24, 2025 | marketbeat.com

Deltec Asset Management LLC Has $19.91 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 21, 2025 | marketbeat.com

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

June 18, 2025 | ophthalmologytimes.comO

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years

June 17, 2025 | uk.finance.yahoo.com

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

June 16, 2025 | globenewswire.com

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

June 11, 2025 | ophthalmologytimes.comO

Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

June 2, 2025 | ophthalmologytimes.comO

H.C. Wainwright maintains $15 target on Ocular Therapeutix stock

May 31, 2025 | investing.com

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews

May 29, 2025 | benzinga.com

Ocular Therapeutix chief scientific officer sells $21,712 in stock

May 29, 2025 | investing.com

Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 1,862 Shares of Stock

May 28, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, OCUL, APGE, and IMCR Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$39.31 +0.31 (+0.79%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$39.29 -0.02 (-0.06%)

As of 07/18/2025 05:57 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Cullinan Therapeutics NASDAQ:CGEM

$7.53 -0.24 (-3.09%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.52 0.00 (-0.07%)

As of 07/18/2025 04:20 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Immunocore NASDAQ:IMCR

$36.31 +0.10 (+0.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$36.29 -0.02 (-0.06%)

As of 07/18/2025 04:04 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Ocular Therapeutix NASDAQ:OCUL

$11.33 -0.05 (-0.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.63 +0.30 (+2.68%)

As of 07/18/2025 05:20 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time